Company intelligence / Profile preview

icotec

Altstätten, St. Gallen, Switzerlandicotec.com ↗

Ownership: Private
Development stage: Commercial

Overview

icotec’s BlackArmor® Carbon/PEEK implants are FDA-cleared for use in spinal tumor and de novo spinal infection indications. The company has achieved significant clinical adoption globally with a track record of clinical success. Its radiolucent implants enable artifact-free imaging for CT/MRI and improved radiotherapy planning. In 2025 it received FDA clearance for treating de novo spinal infections with its devices—the first such approval in the US—and CMS New Technology Add-on Payment status.

Therapeutic areas: OncologyOtherRheumatologyNeurologyInfectious Diseases
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Osteotec Ltd. exclusive UK distribution agreement

Beyond the preview

Go deeper on icotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on icotec.

Explore the full profile